Simulations Plus, known for its work in model-informed and AI-accelerated drug development, has agreed to be acquired by Altaris, a healthcare-focused investment firm, in an all-cash deal. Once the transaction closes, Simulations Plus will become privately held and will no longer trade publicly.
Altaris also intends to combine Simulations Plus with Chemical Computing Group, an existing portfolio company known for its molecular design software used across pharmaceutical, chemical, and materials industries. The combination aims to bring together their simulation and modeling software capabilities to support drug discovery and development. The deal remains subject to customary regulatory and shareholder approvals.
Image generated by: ChatGPT
